心力衰竭与超正常喷射分数:与轻度减少和保存喷射分数相比,临床特征和结果
Amitai Segev1,2, Rotem Tal-Ben Ishay3,4, Marco Metra5
1Cardiovascular Division, The Leviev Heart Center, Sheba Medical Center, Tel-HaShomer, Sheba Rd. 2, Ramat-Gan, Israel. agsegev@yahoo.com.
概括
患有超正常喷射率 (HFsnEF) 的心力衰竭患者表现出明显的特征和更高的并发症负担. 虽然最初似乎有更糟糕的结果,HFsnEF是一个标志物,而不是一个独立的预后因素.
科学领域:
- 心脏病学 心脏病学
- 心脏衰竭研究研究
- 心声回声扫描 (Echocardiography) 是一种心声回声扫描.
背景情况:
- 超正常喷射率心力衰竭 (HFsnEF) 是一种新兴的临床实体,对它的理解有限.
- 现有的研究缺乏关于HFsnEF患者临床概况和结果的全面数据.
研究的目的:
- 阐明HFsnEF的临床特征和结果.
- 为了比较HFsnEF患者与那些轻微减少喷射率 (HFmrEF) 和保存喷射率 (HFpEF) 的患者.
主要方法:
- 对6202名住院和门诊心力衰竭患者的回顾性分析.
- 患者分为HFmrEF (LVEF 41-49%),HFpEF (LVEF 50-64%) 和HFsnEF (LVEF ≥65%) 的患者.
- 分析包括临床,心声学参数,住院率和平均32个月的死亡率.
主要成果:
- HFsnEF患者年龄较大,主要是女性,患高血压的患病率较高, LV 缩, LV 尺寸较小,填充压力较高.
- 单变量分析显示HFsnEF的死亡率更高,但多变量分析显示,经过对混因素进行调整后,没有显著差异.
- HFsnEF和HFpEF组的总住院率相似,而HFsnEF显示了与HF相关的住院率最低.
结论:
- HFsnEF患者具有独特的临床和心声学特征,受年龄和并发症的影响.
- 在HFsnEF中超正常的射出分数似乎是潜在严重性的标记,而不是死亡率的独立预测指标.
- 需要进一步的研究,以了解HFsnEF的具体机制和管理策略.
更多相关视频
相关概念视频
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:26Imbalances in Cardiac Output
1.3K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.3K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
371
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
371
01:22Heart Failure Drugs: Diuretics
334
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
334
01:22Heart Failure Drugs: β-Blockers
308
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
308